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Abstract: 
 
Background: The high-affinity IgE receptor, FcεRI, is unresponsive on mast cells and basophils 
from people in several populations through an unknown mechanism. Similarly, FcεRI-positive 
basophils from ‘nonreleasers’ are IgE-unresponsive and are deficient in the tyrosine kinase 
Syk. Objective: To test the hypothesis that cross-linking FcεRI on mast cells and basophils leads 
to FcεRI nonresponsiveness through reduction in Syk protein levels. Methods: Human mast cells 
and basophils were used to determine if FcεRI hyporesponsiveness correlated with reduced Syk 
levels. Results: It is shown that suboptimal antigen challenge, that did not lead to significant 
mediator release, induced nonresponsiveness and correlated with reduced Syk. Other IgE-
associated signaling molecules were unaffected by the same treatment. The ability of IgE-
unresponsive mast cells to regain FcεRI responsiveness is paralleled by increased cellular Syk 
levels in vitro. The reduction of Syk levels with suboptimal antigen concentrations was calcium 
independent and mediated through a proteasome-dependent mechanism. Conclusion: These 
findings confirm and extend our knowledge about a novel regulatory mechanism for maintaining 
FcεRI in a quiescent state. This mechanism may also explain why low concentrations of allergen 
given to patients during allergen immunotherapy induce FcεRI nonresponsiveness and 
therapeutic benefit without inducing systemic anaphylaxis. 
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Article: 
 
Introduction 
 
Mast cells and basophils are the major effector cells in allergic inflammation. When antigen (i.e. 
pollen) aggregates IgE bound to the high-affinity IgE receptor, FcεRI, on mast cells and 
basophils, it stimulates signaling cascades that lead to allergic mediator release and allergic 
disease (hayfever, asthma). 
 
Allergen immunotherapy has proved to be a successful treatment for people with allergic disease, 
but the mechanism for its efficacy is not known. One hypothesis suggests that allergen 
immunotherapy simply reduces the amount of allergen-specific IgE available for mast 
cell/basophil binding. Thus, when patients are subsequently exposed to the allergen, there are not 
sufficient amounts of specific IgE to sensitize mast cell/basophil FcεRI. In fact, a major anomaly 
exists as most studies find that immunotherapy does not reduce allergen-specific IgE levels 
[1,2,3,4,5,6], although mast cell/basophil-induced reactions are diminished [7,8,9]. Specifically, 
Creticos et al. [1 ]showed that antigen-specific IgE levels do not decrease following allergy 
shots; instead antigen-specific IgE levels initially increase and do not fall below baseline/initial 
levels. 
 
Instead, the intrinsic IgE-induced reactivity of basophils is reduced following immunotherapy. A 
recent study typifies this observation where basophils were obtained before and after 
immunotherapy and challenged with antigen, anti-IgE, or non-IgE-mediated stimuli; 
extracellular serum concentrations of IgE/IgG were not a factor in these experiments [9]. FcεRI-
mediated basophil histamine release was significantly reduced following allergen 
immunotherapy and no decrease in antigen-specific IgE levels was noted [9]. Therefore, while 
basophil FcεRI nonresponsiveness is induced during immunotherapy, there is a paradoxical rise 
in allergen-specific IgE in the serum suggesting that a simple reduction in allergen-specific IgE 
cannot explain its efficacy. 
 
Like basophils, mast cell nonresponsiveness occurs in patients who have undergone successful 
allergen immunotherapy where a reduction in the skin prick test, which measures skin mast cell 
IgE-mediated degranulation in response to antigen challenge, is a strong predictor for clinical 
efficacy [10]. Similarly, patients allergic to certain drugs (i.e. penicillin) can be ‘rush’ 
desensitized by injection of the drug at concentrations that do not trigger an allergic response 
[11]. 
 
While it is clear that mast cells and basophils are capable of being induced to nonresponsiveness 
by certain in vivo and in vitro scenarios, the mechanisms leading to FcεRI nonresponsiveness are 
not known. It was hypothesized, based on the observation that the phenotype of IgE 
nonresponsive mast cells and basophils was similar to naturally occurring, Syk-deficient 
‘nonreleaser’ basophils [12] and lung mast cells [13], that antigen stimulation could induce 
FcεRI nonresponsiveness and Syk protein reduction. We challenged human skin mast cells with 
optimal and suboptimal concentrations of antigen and measured mediator release and Syk 
expression. We show that the induction of IgE nonresponsive skin mast cells and peripheral 
blood basophils correlates with reduced Syk protein levels. Suboptimal antigen stimulation of 
freshly purified peripheral blood basophils also resulted in reduced Syk levels. These data 
suggest that human FcεRI nonresponsiveness is linked to the levels of Syk which can be 
dramatically reduced in suboptimally challenged cells. 
 
Materials and Methods 
 
Reagents 
 
Monoclonal antiphosphotyrosine (pY) and anti-Lyn Abs were obtained from Santa Cruz 
Biotechnology, Santa Cruz, Calif., USA. Antiactin was from Sigma, St. Louis, Mo., USA. The 
anti-Syk, anti-Cbl, and anti-FcεRI-γ Ab were obtained from Upstate, Lake Placid, N.Y., USA. 
The chimeric human anti-4-hydroxy-3-nitrophenacetyl (NP) IgE Ab and the antigen it detects, 
NP-BSA, were from Serotec (Oxford, UK) or purified from the cell line JW8 (ATCC, Fairfax, 
Va., USA). IgE is centrifuged at 60,000 g to remove any aggregates. The proteasome inhibitors 
PSI and MG-132 were from Calbiochem, San Diego, Calif., USA. The antibody 22E7 to the 
FcεRI-α chain was a generous gift from Dr. J. Kochan. 
 
Tissue Mast Cells 
 
Skin mast cells were purified and cultured as described [14]. Fresh samples of skin or lung were 
obtained from surgical specimens at the Virginia Commonwealth University Health Systems or 
through the Cooperative Human Tissue Network of the National Cancer Institute (Columbus, 
Ohio, USA). All studies were approved by the Human Studies Committee at Virginia 
Commonwealth University Health Systems. Tissue was cutinto fragments and incubated in a 
solutioncontaining collagenase, hyaluronidase DNase, and 1% fetal calf serum (digestion buffer) 
for 2 h at37°C with constant stirring. The dispersed cells were separatedfrom residual tissue by 
filtration and suspended in HBSS containing 1% FCS and 10 mM 4-(2-hydroxyethyl)-1-
piperazine-ethanesulfonicacid (HEPES; washing buffer). The remaining tissue was subjectedto 
two additional digestions as above, and combined with the cellsfrom the first digestion. Cells 
were resuspended in washing buffer, layered over Histopaque and centrifugedat 700 g at room 
temperature for 20 min. 
 
Enriched skin cells were suspended at 1 × 106 cells/ml in serum-free AIM-V medium (Life 
Technologies, Rockville, Md., USA) containing 100 ng/ml rhuSCF (Biosource) in 24-well plates 
(Costar). When the cell number reached approximately 2 × 106 cells/ml, half the cells were split 
to another well with fresh medium. Cell numbers per sample were adjusted to account for the 
cells that were split.Total cell number and viability were assessed by trypan blue 
staining.Cultures were maintained for up to 2 months and were approximately 100% skin mast 
cells. 
 
Peripheral Blood Basophils 
 
Venous blood (100–300 ml) was collected from healthy, nonmedicated donors who had given 
informed consent. Basophils were purified as previously described [15, 16]. 
 
Measurement of Degranulation and Cytokine Production 
 
All samples were run in duplicate. Mast cells were sensitized with human anti-NP IgE (1–5 
µg/ml) for at least 24 h. In some experiments, the proteasome inhibitors PSI or MG-132 (10–100 
µM) were added to the cells 30 min prior to activation. Duplicate samples (1–5 × 
105 cells/condition) were washed and activated in AIM-V media plus 100 µg/ml of soybean 
trypsin inhibitor with or without NP-BSA. After 30 min, cells were centrifuged and 25 µl of 
media removed for β-hexosaminidase measurement [17]. Cells were suspended in the remaining 
media and incubated in a CO2 incubator for 24–52 h. Cells were centrifuged and the supernatants 
stored at –70°C until cytokine measurement. In some experiments IgE-sensitized cells were 
incubated for 30 h with suboptimal concentrations (0.01–0.1 ng/ml) of NP-BSA, washed and 
rechallenged as above. 
 
Cytokines were measured using an in-house ELISA. Briefly, granulocyte monocyte-colony-
stimulating factor (GM-CSF) or tumor necrosis factor-α (TNF-α) Abs (Pharmingen, San Diego, 
Calif., USA) were diluted in PBS/1% BSA/Tween (2 µg/ml) and used to coat 384-well plates 
(Nalge-Nunc, Rochester, N.Y., USA), 4°C for 24 h. The plates were washed 2 times with 
PBS/Tween and blocked by adding 200 µl blocking buffer (PBS/1% BSA) for 2 h at room 
temperature. The plates were washed 4 times with PBS/Tween and 100 µl of standards or 
samples, diluted in PBS/1% BSA/Tween, were added for 24 h at 4°C. Plates were washed 4 
times and 100 µl of detection Abs was added for 1 h at room temperature, washed 6 times and 
100 µl of a 1:1,000 dilution of Avidin-HRP (Jackson, Bar Harbor, Me., USA) diluted in PBS/1% 
BSA/Tween was added to each well for 30 min at room temperature. After washing 6 times 100 
µl of substrate (100 µl of 3% H2O2 to 11 ml 2,2′-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid 
diluted 0.3 mg/ml in 0.1 M anhydrous citric acid) was added and the OD at 405 nm was 
measured after 10–20 min. 
 
Basophils were challenged for 30 h in Hanks’ balanced salt solution [15] with or without 22E7, 
anti-IgE, or antigen (Indoor Biotechnologies, Charlottesville, Va., USA). Histamine release was 
measured as previously described [15]. 
 
To examine the rebound in cellular Syk levels and FcεRI responsiveness, NP-IgE-sensitized mast 
cells (0.5–10 × 106 cells/condition) were challenged with or without 0.1 ng/ml of antigen for 24–
30 h (to induce desensitization). Cells were washed 3× with AIM-V medium and suspended in 
AIM-V + SCF for the indicated times. Cells were washed 2× in protein-free medium and 
subjected to SDS-PAGE and Western blotting as described below. Duplicate samples, treated in 
parallel, were resensitized with IgE (10 ng/ml) and used to determine FcεRI responsiveness with 
optimal antigen concentrations. 
 
[Ca2+]i Measurement using Fura-2 Fluorescence 
 
NP-IgE-sensitized mast cells were adhered to coverslips coated with 0.1% gelatin for 24 h. Cells 
were loaded with the Ca2+-sensitive probe Fura-2/acetoxymethy (2 µmol/l) for 30 min in a 
CO2incubator at 37°C. After loading, cells were washed and incubated in HBSS without cross-
linker to obtain a baseline reading followed by the addition of HBSS containing various 
concentrations of NP-BSA. Intracellular calcium ([Ca2+]i) was measured using an IX-50 inverted 
fluorescence microscope (Olympus, Tokyo, Japan) in conjunction with a xenon arc excitation 
source, a photomultiplier, and a photon counter (Ionoptix, Milton, Mass., USA). Data were 
acquired and analyzed with Ionwizard software provided by the manufacturer. Epifluorescence 
was measured from ≥5 mast cells, and the values in [Ca2+]i determined as the fluorescence 
ratio (R) ofCa2+-bound Fura-2 (340 nm) to unbound Fura-2 (380 nm), withemission collected at 
510 nm. R was converted to free Ca2+ concentration using an in vitro standard curve generated 
with a calibration kit (Molecular Probes, Eugene, Oreg., USA). 
 
Small Inhibitory RNA-Mediated Inhibition of Syk Expression 
 
Four pooled SMARTselected human Syk small inhibitory RNA (siRNA) duplexes with UU 
overhangs and a 5′-phosphate on the antisense strand were obtained from Dharmacon Research, 
Lafayette, Colo., USA. As a control, four nonspecific siRNAs with equal GC content were used. 
The siRNA duplex was introduced into human skin mast cells using a liposome transfection 
approach. Liposome/siRNA complexeswere formed at room temperature using 5 µl of 20 
µM siRNA, 3 µl of LipofectAMINETM 2000 (Invitrogen), and 100 µl of serum-free DMEM 
culturemedium (Invitrogen). The resulting solution was added dropwise to each 24-well culture 
dish containing ∼1 × 105 MCs. The cells were incubated 4 h at 37°C. One milliliter of serum-
enriched medium was then added, and the cells were culturedfor an additional 30 h. The 
transiently transfected cells were harvested, and IgE-mediated degranulation and cytokine 
production measured after IgE sensitization. In parallel, the levels of Syk and actin protein were 
measured using the below SDS-PAGE immunoblot approach. 
 
Western Blotting 
 
Mast cells were lysed in denaturing lysis buffer at 0.5–10 × 107 cells/ml. The protocol for this is 
described by Tkaczyk et al. [18]. Expression of Syk, Lyn, and actin protein was measured by 
Western blotting as previously described [12, 15]. 
 
Band intensities were quantitated using a molecular imaging package from Biorad (The 
Discovery Series, Quantity One, Quantitative Software). In some experiments band intensities 
are presented as a ratio of Syk to actin to compensate for gel loading and blot stripping/reprobing 
variations. Degranulation was measured in each Western blotting/immunoprecipitation 
experiment by measuring β-hexosaminidase as described above. 
 
Results 
 
FcεRI Nonresponsiveness due to Long-Term Antigen Stimulation 
 
The mechanism for FcεRI nonresponsiveness after long-term antigen stimulation is not clear and 
has not been demonstrated with human mast cells. We tested human skin mast cells for their 
ability to become unresponsive to IgE stimuli following long-term antigen stimulation. NP IgE-
sensitized cells were challenged with or without optimal (10 ng/ml) or suboptimal (0.1 ng/ml) 
concentrations of NP-BSA up to 52 h. Supernatants were collected after this initial 
desensitization step and examined for degranulation (prerelease). Cells were resensitized with 
IgE for 2 h, washed, and rechallenged with optimal concentrations of NP-BSA for 30 min and β-
hexosaminidase measured in the supernatants. As expected, no desensitization was observed in 
cells not exposed to cross-linker (fig. 1a) and optimal concentrations of antigen induced robust 
degranulation (fig. 1c). As shown in figure 1b, FcεRI-mediated degranulation was optimally 
inhibited when cells were first exposed to suboptimal concentrations of antigen for 24 h. This 
nonresponsiveness was not simply due to the loss of IgE as FACs analysis with FITC-labeled 
anti-IgE Abs revealed the presence of IgE for up to 3 days postsensitization (fig. 1d). 
Compounds which bypass FcεRI (A23187) induced a robust response indicating a specific defect 
in the FcεRI signal transduction pathway, reminiscent of nonreleaser basophils. 
 
 
Fig. 1. In vitro desensitization of FcεRI on human skin mast cells. Skin mast cells (2 × 105 cell/well) were sensitized 
with NP-IgE (1 µg/ml), washed and challenged for 24 or 52 h with no cross-linker (a), suboptimal (0.1 ng/ml; b) or 
optimal (10 ng/ml; c) concentrations of NP-BSA. β-Hexosaminidase was measured in the supernatants (prerelease). 
Cells were resensitized with IgE and challenged with optimal concentrations of NP-BSA (10 ng/ml) or A23187 (5 
µM) for 30 min. All experiments were performed in duplicate. The results show the standard error of the mean from 
3 separate experiments. d Skin mast cells were incubated with (+) or without (–) IgE and desensitized with 
suboptimal concentrations of NP-BSA for 52 h (as in b). Cells were washed and resensitized (+IgE) or not (–IgE) 
with NP-IgE. They were washed and incubated with FITC-labeled anti-IgE and analyzed by FACs. 
 
Previous studies showed decreased levels of Syk protein were associated with human basophil 
FcεRI nonresponsiveness [12, 19] and human mast cells may have a similar nonreleaser 
phenotype [13]. Thus, it was hypothesized that nonresponsive skin mast cell FcεRI induced by 
suboptimal antigen stimulation was due to decreased Syk levels. As shown in figure 2a, NP-IgE-
sensitized skin mast cells begin to lose Syk expression at antigen concentrations which did not 
induce detectable degranulation and 10,000 times less (0.001 ng/ml) than that required for 
optimal degranulation (10 ng/ml). Syk was decreased in cells challenged from 0.0001 to 10 
ng/ml of antigen for 24 h, while Lyn levels remained unchanged. High doses of antigen (>100 
ng/ml), which causes excessive receptor cross-linking and reduced mediator release, did not 
reduce Syk levels. No changes were noted in FcεRI-γ protein levels under the same conditions 
(data not shown). Challenge with suboptimal concentrations of antigen reduce Syk levels at 
approximately 24 h; shorter incubation times did not reduce Syk levels (fig. 2b). Similar results 
were observed with highly purified human lung mast cells (not shown). 
 
Peripheral blood basophils are similar to tissue mast cells as both cell types express high 
amounts of FcεRI which mediates IgE degranulation. Freshly purified basophils were challenged 
with or without FcεRI stimulation for 24–30 h and Syk expression examined by Western blot. As 
seen in figure 2c, basophil Syk is reduced in response to IgE-mediated stimulation. As with mast 
cells, Syk reduction occurred at antigen concentrations that did not induce noticeable 
degranulation (0.01 ng/ml). These results suggest that suboptimal FcεRI cross-linking induces 
basophil nonresponsiveness through a mechanism which reduces Syk levels. In addition, reduced 
Syk levels due to low concentrations of IgE receptor cross-linker may be a common mechanism 
regulating human FcεRI cellular responsiveness. 
 
 
Fig. 2. FcεRI desensitization on human skin mast cells correlates with reduced levels of Syk. NP-IgE-sensitized skin 
mast cells (1.8–2.0 × 106 cell equivalents/lane) were challenged for >24 h with or without increasing concentrations 
of cross-linker (a) or with or without 0.1 ng/ml of cross-linker for various times (b). Cells were washed, lysed, and 
separated by SDS-PAGE and Western blotted with antibodies against Syk, Lyn or actin as described in Methods. 
Supernatants from parallel-treated cells were examined for degranulation. Results are representative of 2 separate 
experiments. c Peripheral blood basophils (98% purity) were challenged for 30 h with varying concentrations of 
anti-IgE receptor antibodies (22E7) and Syk levels monitored with Western blotting (3.2 × 105 cell 
equivalents/lane). The error bars in the densitometric analysis represent results from 3 separate experiments. 
 
Reduction in Syk Levels and Cytokine Release from Human Skin Mast Cells 
 
We next determined if Syk reduction occurred at antigen concentrations which induce mast cell 
cytokine production. As seen in figure 3, densitometric analysis demonstrated reduced Syk levels 
at antigen concentrations that did not induce degranulation or the production and secretion of 
TNF-α and GM-CSF. Similar results were obtained with IL-5 cytokine production (data not 
shown). Thus, suboptimal doses of antigen induce Syk reduction at concentrations 1,000 times 
less than that required for cytokine production. 
 
 
Fig. 3. FcεRI-induced Syk reduction occurs at antigen concentrations that do not induce degranulation or cytokine 
production. NP-IgE-sensitized skin mast cells were challenged for 30 min (β-hexosaminidase, β-Hex) or 24 h (GM-
CSF, TNF-α or Syk levels) with or without increasing concentrations of cross-linker. Supernatants were collected 
and assayed for mediator release. Cells were washed, lysed, and separated by SDS-PAGE and Western blotted with 
antibodies to and Syk and bands visualized with ECL (not shown). The Syk blots were scanned and band intensities 
quantitated using densitometric analysis. Results show the standard error of the mean from 4 (degranulation) or 3 
(cytokine release) experiments. 
 
Syk Is Reduced with Suboptimal Antigen Stimulation through a Calcium-Independent, 
Proteasome-Dependent Mechanism 
 
The mechanism leading to antigen-induced Syk deficiency was further explored. Reduced Syk 
levels with suboptimal antigen concentrations (0.001–0.1 ng/ml) occurred at concentrations that 
were independent of the release of [Ca2+]i store release (fig. 4a). Monitoring [Ca2+]i in response 
to suboptimal concentrations inducing Syk deficiency (0.001 and 0.01 ng/ml) for longer periods 
of time (up to 6 h) failed to detect store release (not shown). As seen in figure 4b, skin mast cells 
incubated with suboptimal antigen had low levels of Syk. However, Syk levels and IgE-mediated 
degranulation were increased under these conditions if the proteasome inhibitors PSI or MG-132 
were added to the cells before FcεRI challenge. We also observed similar Syk mRNA levels in 
cells challenged with suboptimal antigen concentrations and nonchallenged cells (data not 
shown). These results suggest that mast cell challenge with suboptimal antigen concentrations 
induces a reduction in Syk protein through a posttranslational, proteasome-dependent 
mechanism. 
 
 
Fig. 4. a Syk reduction with suboptimal antigen concentrations is calcium independent. Fura-2-labelled mast cells 
were challenged with the indicated concentrations of NP-BSA (arrows) and the [Ca2+]i measured for 500 s, indicated 
on the y-axis, as described in Methods. In parallel, similarly treated mast cells were Western blotted sequentially 
with Syk and actin Abs and the band intensities presented as a ratio as described above. b Proteasome inhibitors 
block FcεRI-induced Syk reduction. NP-IgE-sensitized mast cells (1.2 × 106 cell equivalents/lane) were challenged 
for 24 h with or without 0.1 ng/ml of cross-linker. Some cells were treated with the proteasome inhibitor PSI or MG-
132 (100 µM) for 30 min prior to challenge. Cells were washed, lysed, and separated by SDS-PAGE and Western 
blotted sequentially with antibodies against Syk and actin as described in Methods. Supernatants from parallel-
treated cells were examined for degranulation after 38-hour challenge with NP-BSA and expressed as the percent 
release of β-hexosaminidase. Results are representative of 2 separate experiments. 
 
A Rebound in Cellular Syk Correlates with FcεRI Responsiveness 
 
Based on the observation that antigen-induced FcεRI nonresponsiveness correlated with reduced 
Syk levels, we investigated if a rebound in Syk levels correlated with the loss of FcεRI 
nonresponsiveness. IgE-sensitized mast cells were challenged with suboptimal antigen 
concentrations as above. Cells were washed free of antigen. IgE-mediated degranulation and Syk 
levels were monitored at different time points. As expected, Syk levels were dramatically lower 
in cells challenged for 30 h with suboptimal antigen and the cells failed to respond to FcεRI 
stimuli (fig. 5a). Cells began to respond to antigen between 12 and 24 h postantigen challenge; 
cells examined at shorter time points remained IgE nonresponsive and had reduced Syk levels. 
Increased Syk levels were observed at approximately 18 h after removal of antigen and 
paralleled the loss of FcεRI nonresponsiveness(fig. 5a). 
 
 
Fig. 5. a Increased Syk levels parallel the loss of FcεRI desensitization. NP-IgE-sensitized mast cells were 
challenged with or without 0.1 ng/ml of NP-BSA for 30 h. Cells were washed and incubated in medium containing 
NP-IgE (10 µg/ml). Degranulation (5 × 105 total cells) and Syk levels (2.2 × 106 cells/time point) were monitored at 
0, 6, 12 and 24 h after the removal of antigen. For degranulation, cells were challenged with or without optimal 
concentrations of antigen (in duplicate as in fig. 1) and the percent β-hexosaminidase release calculated in the 
supernatant. In parallel, Syk levels were measured by Western blot. Results are representative of 3 similar 
experiments. b Reduction in Syk protein correlates with reduced IgE-mediated degranulation and cytokine 
production. Mast cells (2.0 × 105 cells/ml) were transfected with Syk siRNA (siRNA+), scrambled controls (siRNA–
), or no siRNA (control). Each group was examined for mediator release by sensitizing with NP-IgE (10 µg/ml) for 
2 h and challenging with antigen (left panel) or examined for Syk levels by SDS-PAGE and Western blotting as 
described (right panel). The asterisk indicates a significant decrease in degranulation (p = 0.024) and cytokine 
production (p = 0.03) using the Student t test in conditions pooled from 3 different experiments. 
 
To further determine a cause and effect relationship between reduced Syk levels and inhibition of 
mast cell mediator release we used siRNA to evaluate the consequences of decreased Syk 
expression in human skin mast cells. As seen in figure 5b, inhibition of Syk expression in skin 
mast cells resultedin an inhibition of IgE-mediated degranulation and cytokine production. The 
siRNA treatment did not affect total β-hexosaminidase levels inside the cell (data not shown). 
These data further support a critical role of Syk in human mast cell signal transduction. In 
addition, these are the first data demonstrating the ability of skin mast cells to be transfected with 
siRNA duplexes. 
 
Discussion 
 
We previously showed that nonreleaser basophils, which also demonstrate FcεRI 
nonresponsiveness, had reduced Syk levels [12, 19]. We hypothesized that low concentrations of 
antigen could induce FcεRI nonresponsiveness through a reduction in Syk protein. In the studies 
presented here we demonstrate that human skin mast cell FcεRI becomes nonresponsive with 
antigen concentrations that do not induce significant mediator release. This nonresponsiveness 
correlates with reduced levels of Syk, similar to nonreleaser basophils. Low concentrations of 
antigen also lead to reduced Syk levels in peripheral blood basophils. Syk appears to be 
downregulated through proteasome degradation as agents that block these events also block Syk 
reduction. The initial steps leading to Syk reduction appear to be calcium independent. When 
antigen is removed the mast cells become responsive to IgE-mediated stimuli after 24 h in 
culture. The loss of FcεRI nonresponsiveness paralleled increases in Syk levels. The observation 
that reduced Syk levels occurs at the protein level is similar to those observed in nonreleaser 
basophils [19,20,21]. 
 
Our data demonstrates that the loss of Syk occurs only after prolonged incubation with antigen. 
This is very different from what was reported in the original description of ‘desensitization’ of 
basophils [22,23,24]. In these studies desensitization occurred within minutes when the cells 
were challenged with antigen in the absence of calcium. This acute mechanism for FcεRI 
downregulation does not appear to involve FcεRI/antigen internalization or Syk loss. Recent 
studies by MacGlashan [25 ]demonstrated that antigen stimulation of basophils induces 
downregulation operating before or at the level of Syk phosphorylation. In these experiments 
basophils were challenged with antigen for less than 2 h before challenge with anti-IgE. The 
levels of Syk phosphorylation were transient with antigen stimulation and no reduction in Syk 
levels was noted, probably due to the reduced prechallenge time. 
 
Recent studies by this group found that optimal and suboptimal concentrations of antigen led to 
reduced Syk expression similar to what was observed in the present study (fig. 2c) [21]. The 
studies presented here confirm the studies in basophils and extend these observations in skin 
mast cells. Taken together, these results suggest reductions in Syk levels through antigen 
stimulation may act to keep these inflammatory cells in a quiescent state. 
 
We also observed that Syk levels were lower in mast cells/basophils that were optimally 
challenged with antigen but had maximal mediator release. This is not surprising in that 
degranulation occurs within 30 min following activation while cytokine production occurs after 
24 h. Therefore, there are likely adequate amounts of Syk protein to mediate the signaling 
cascade leading to mediator release. 
 
We observed that antigen-induced Syk reduction was mediated through ubiquitination and 
proteasomal degradation. Rodent mast cell-like cells (RBL-2H3) and human basophils 
demonstrated Syk ubiquitination after FcεRI engagement with optimal concentrations of antigen 
and suggest a similar molecular mechanism for downregulation of receptor complexes by 
targeting ubiquitinated Syk to the proteasome for degradation [21, 26]. The mechanisms 
presented here and previously may explain how a ‘resting’ cell remains nonactivated after 
suboptimal antigen challenge while Syk reduction with optimal concentrations of antigen is 
consistent with a mechanism for ‘turning off’ ongoing mast cell mediator responses. 
 
The precedence for selective protein degradation through activation of immune receptors is 
strong. Ubiquitination is a posttranslational modification that controls the fate of proteins 
through selective proteasome degradation. In antigen-stimulated T cells, ZAP-70 (a kinase 
similar to Syk) is rapidly degraded via a calpain-dependent mechanism [27]. Paolini and Kinet 
[28] found FcεRI engagement on RBL-2H3 resulted in Syk ubiquitination and Syk kinase 
activity is required for its own ubiquitination [29]. Similarly, B cell receptor stimulation induces 
Syk ubiquitination [30, 31]. Others have shown that both Syk and ZAP-70 become ubiquitinated 
in response to antigen stimulation in other cell types [32]. Receptor-mediated activation of other 
kinases similarly ‘tags’ them for ubiquitination-dependent degradation [26, 33, 34]. 
 
It is possible that low concentrations of antigen induces IgE nonresponsiveness through a Syk-
independent mechanism. However, we showed that reducing the level of Syk with siRNA 
correlated with reduced IgE signaling leading to mediator release (fig. 5b). This was expected as 
we and others have demonstrated that FcεRI-induced mediator release is dependent on the levels 
of Syk protein [12, 20, 35]. Reduction in levels of other molecules leading to a lack of IgE-
mediated degranulation have been reported in rodent cells [36, 37], while Lyn deficiency appears 
to have little affect [38]. Nonetheless, adequate quantities of Syk are clearly required for a full 
response through FcεRI on human mast cells. 
 
The implications for these studies are far-reaching. No hypothesis has been able to explain how 
graded increases in allergen dosing (up to 15–20 µg of major allergen) given during 
immunotherapy can be injected without inducing anaphylaxis. It has been assumed that as the 
dose of allergen is slowly titrated up, some degree of ‘tolerance’ is induced which renders the 
next dose safe. It is plausible that the mechanisms underlying chronic allergen stimulation and 
concomitant FcεRI nonresponsiveness may involve decreased Syk levels resembling nonreleaser 
mast cells/basophils. How could chronic, low-dose antigen stimulation induce degradation of 
FcεRI-specific kinases without affecting protein levels in other cells (as with nonreleaser 
basophils and possibly mast cells)? The following hypothesis is proposed (fig. 6). 
 
 
Fig. 6. Chronic antigenic stimulation results in lower Syk kinase levels. Normally, when atopic donors are 
challenged with antigen there is degranulation mediated through Syk. However, low doses of antigen challenge, 
through allergen immunotherapy, suboptimally cross-link surface-bound IgE on mast cells and basophils resulting in 
the proteasome degradation of Syk. When cells are then antigen challenged there is less Syk signaling and thus 
inhibited mediator release. 
 
Allergen immunotherapy, which aims to induce FcεRI nonresponsiveness with suboptimal doses 
of antigen, initially induces antigen-specific IgE and is given at a dose that does not result in 
noticeable symptoms. Fatalities have been associated with allergen skin testing and 
immunotherapy; thus ensuring the patient receives a dose of allergen that will induce 
desensitization – but not anaphylaxis – is an important safety concern. Low IgE-FcεRI cross-
linking leads to the downregulation and degradation of FcεRI receptor-associated kinases 
through ubiquitination and proteasome degradation. The recurrent stimulation (induction 
involves weekly shots) with increasing doses of allergen would ensure continued, subacute 
activation and kinase ubiquitination, while the specific, high-affinity interaction between mast 
cell/basophil surface IgE with antigen would ensure only downregulation of kinase levels in 
these cells. In preliminary experiments we found that donors undergoing specific allergy 
vaccination have reduced basophil histamine release (as others have found [9]) and undetectable 
levels of Syk during the initial up-dosing period (Kepley, unpubl. data). The data presented here 
and previously [21] provide mechanistic evidence to support the above hypothesis. 
 
In conclusion, we show that proteasome-mediated degradation of FcεRI-associated Syk with low 
concentrations of antigen, for extended periods of time, leads to FcεRI nonresponsiveness on 
mast cells. We also confirm previous studies in human basophils by demonstrating that antigen 
challenge induces reductions in Syk protein levels. The resulting reduction in kinase levels 
would blunt the signaling process and inhibit IgE cell responsiveness to antigenic stimulation. 
This mechanism may account for the clinical success observed during the initial, ‘up-dosing’ that 
occurs with allergen immunotherapy. 
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